Accelerating Lead Optimization Away from Anti-Targets: Navigating the Structural Complexity of Promiscuous ADMET Proteins
The development of a small molecule suitable for clinical use involves optimization of ligand binding to an identified target protein but also frequently the reduction of binding to a variety of anti-target proteins known to pose translational risk. These anti-targets, often referred to as ADMET proteins, often conta...